Fudim, M., Lopes, R. D., Wojdyla, D. M., Mehran, R., Khan, M. S., Granger, C. B., … Alexander, J. H. (2022). Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. In CIRCULATION (Vol. 146).

Fudim, Marat, Renato D. Lopes, Daniel M. Wojdyla, Roxana Mehran, Mohammad S. Khan, Christopher B. Granger, Shaun G. Goodman, Ron Aronson, Stephan Windecker, and John H. Alexander. “Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.” In CIRCULATION, Vol. 146, 2022.

Fudim M, Lopes RD, Wojdyla DM, Mehran R, Khan MS, Granger CB, et al. Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. In: CIRCULATION. 2022.

Fudim, Marat, et al. “Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.” CIRCULATION, vol. 146, 2022.

Fudim M, Lopes RD, Wojdyla DM, Mehran R, Khan MS, Granger CB, Goodman SG, Aronson R, Windecker S, Alexander JH. Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. CIRCULATION. 2022.